• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

    7/25/23 4:06:11 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email
    SC 13D/A 1 cosm_sc13da.htm SC 13D/A cosm_sc13da.htm

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    COSMOS HOLDINGS, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.001 per share

    (Title of Class of Securities)

     

    221413206

    (CUSIP Number)

     

    Elliot H. Lutzker, Davidoff Hutcher & Citron LLP, 605 Third Avenue, New York, NY 10158

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    July 20, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 

    221413206

     

     

    1

     

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Grigorios Siokas

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

    PF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Greece

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    SOLE VOTING POWER

    2,540,268

    8

    SHARED VOTING POWER

    -0-

    9

    SOLE DISPOSITIVE POWER

    2,540,268

    10

    SHARED DISPOSITIVE POWER

    -0-

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,540,268

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    17.79%

    14

    TYPE OF REPORTING PERSON (See Instructions)

    IN

     

     
    2

     

     

    Item 1. Security

    and Issuer:

    Common Stock, $.001 par value

     

    Cosmos Holdings, Inc., 141 West Jackson Boulevard, Suite 4326, Chicago, IL 60604

     

    Item 2. Identity and Background

     

    (a)

    Grigorios Siokas

     

     

    (b)

    5AG Georgiou Str., Pilea, Thessaloniki J3TK 57001

     

     

    (c)

    CEO, Cosmos Holdings, Inc., 141 West Jackson Boulevard, Suite 4236, Chicago, IL 60604

     

     

    (d)

    No criminal proceedings to be disclosed

     

     

    (e)

    No civil proceedings to be disclosed

     

     

    (f)

    Greece

     

    Item 3. Source and Amount of Funds or Other Considerations Personal funds, none of which have been borrowed.

     

    Item 4. Purpose of Transaction There are no plans or proposals which the reporting person has which may result in any of the matters listed.

     

    Item 5. Interest in Securities of the Issuer

     

    (a)

    2,540,268 (17.79%) shares based on 13,068,719 shares issued and outstanding on July 21, 2023.

     

     

    (b)

    Sole voting power and disposition power – 2,540,268 shares; includes 1,327,885 issued shares; 212,383 shares issuable upon exercise of Exchange Warrants issued on October 20, 2022, pursuant to a Warrant Exchange Agreement dated as of October 3, 2022; 500,000 shares issuable upon exercise of Series A Common Warrants exercisable at $3.00 per share sold pursuant to Registration Statements 333-267505 and 333-267917 (the “Registration Statements”); and 500,000 shares issuable upon exercise of Series B Common Warrants exercisable at $3.00 per share sold pursuant to Registration Statement No. 333-267917.

     

     

    (c)

    On July 21, 2023, Mr. Siokas entered into a Stock Purchase Agreement pursuant to which he purchased 181,451 shares of common stock (with no accompanying warrants) at a price of $2.48 per share, or an aggregate of approximately $450,000.  The securities were purchased from the issuer pursuant to a registered direct offering priced at-the-market pursuant to Registration Statement No. 333-267550 and the Prospectus Supplement contained therein dated July 21, 2023.

     

     

    (d)

    No person has the right to receive, or the power to direct the receipt of dividends from, or proceeds from, the sale of such securities.

     

     

    (e)

    Not applicable.

     

     
    3

     

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer; None

     

    Item 7. Material to Be Filed as Exhibits; None

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    July 25, 2023

     

    Dated

     

     

     

    /s/ Grigorios Siokas

     

    Signature:

     

     

     

    Grigorios Siokas/Chief Executive Officer

     

    Name/Title

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     
    4

     

    Get the next $COSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

      SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

      11/14/24 4:50:24 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cosmos Health Inc.

      SC 13G - Cosmos Health Inc. (0001474167) (Subject)

      2/14/24 3:33:29 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

      SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

      7/25/23 4:06:11 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

      CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp

      5/7/25 2:30:10 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

      CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was not

      5/6/25 1:40:33 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

      CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

      4/30/25 12:50:09 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/28/25 10:49:44 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/25/25 10:07:34 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/24/25 9:48:15 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/28/25 10:49:44 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/25/25 10:07:34 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/24/25 9:48:15 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    SEC Filings

    See more
    • Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Cosmos Health Inc. (0001474167) (Filer)

      5/7/25 1:30:41 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by Cosmos Health Inc.

      10-K - Cosmos Health Inc. (0001474167) (Filer)

      4/15/25 4:36:30 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form NT 10-K filed by Cosmos Health Inc.

      NT 10-K - Cosmos Health Inc. (0001474167) (Filer)

      3/31/25 4:33:37 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

      CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

      4/16/25 12:45:15 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

      CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

      12/26/24 1:30:00 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

      THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

      11/21/23 9:00:00 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Financials

    Live finance-specific insights

    See more
    • Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

      CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

      4/30/25 12:50:09 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

      CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

      1/21/25 3:00:00 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Issues Letter to Shareholders

      CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

      11/12/24 12:01:41 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care